NorthStrive Biotherapeutics
Private Company
Total funding raised: $15M
Overview
NorthStrive Biotherapeutics is targeting a significant gap in the rapidly expanding obesity therapeutics market by developing a muscle-preserving adjunct therapy. Its first-in-class asset, EL-22, is an oral engineered probiotic that activates the immune system to generate anti-myostatin antibodies, aiming to counteract the lean muscle loss associated with potent GLP-1 drugs. Having completed a Phase 1 trial in healthy volunteers, the company is positioning EL-22 for obesity and is led by a small management team with financial and scientific expertise. NorthStrive operates as a private, pre-revenue entity seeking to create a next-generation combination treatment paradigm for obesity.
Technology Platform
Engineered probiotic platform using modified Lactobacillus casei to deliver antigens orally, stimulating a targeted systemic immune response (e.g., anti-myostatin antibodies).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NorthStrive competes in the emerging niche of muscle preservation for obesity. Competitors include biotech companies developing injectable anti-myostatin antibodies (e.g., Pfizer's domagrozumab, though not for obesity), activin receptor inhibitors, and other myostatin-targeting modalities. Large pharma companies like Eli Lilly and Novo Nordisk are also likely investigating combination strategies internally, posing a significant competitive threat.